Join us Dec. 1-3 in Nashville for the Digiday Programmatic Marketing Summit
Mushroom boardroom: Why some execs are using psychedelics to get through the workday
This is a preview of a story that was initially published on our sister site, WorkLife, which covers the future of the workplace.
After his father died in 2018, Paul Marlow struggled with fear, anxiety and depression. That’s when he turned to microdosing psychedelics as a remedy — and he hasn’t looked back.
Microdosing, he said, helps him focus at work. As the pandemic persists, many who are looking for a jolt of motivation, inspiration or medication are turning to microdosing — that is, ingesting small amounts of psychedelic drugs to combat mental health issues and enhance creativity, productivity and physical well-being. Read the full story on WorkLife.
More in Marketing
Future of Marketing Briefing: Creators had a big year. Christmas still went to the celebrities
Despite leaning on creators for most of the year, marketers aren’t doing it for the holiday crunch. That job still belongs to celebrities.
In graphic detail: Six thousand brands later, ChatGPT ads still have a conversion problem
OpenAI has ambitious ad revenue targets, which depend on advertiser demand, measurement and monetisation.
Agencies find AI overuse is leading to brief bloat
Agencies and marketers now frequently use AI tools to create media and creative briefs. But the practice could be a canary in the coalmine for AI overuse in advertising.